Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Antiviral Agents/hzVSF-v13 Combination Therapy vs Oral Antiviral Monotherapy in Chronic Hepatitis B Patients

NCT05808335 is registered in ClinicalTrials.gov with ImmuneMed, Inc. as lead sponsor.

NCT NCT05808335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05808335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Antiviral Agents/hzVSF-v13 Combination Therapy vs Oral Antiviral Monotherapy in Chronic Hepatitis B Patients
Lead sponsor
ImmuneMed, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
January 11, 2022
Completion date
December 4, 2024
Enrollment
32 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b